Literature DB >> 33441537

Conditional relative survival among patients with follicular lymphoma: a population-based study in the Netherlands.

Manette A W Dinnessen1, Otto Visser2, Sanne H Tonino3, Eduardus F M Posthuma4,5, Nicole M A Blijlevens6, Marie José Kersten3, Pieternella J Lugtenburg7, Avinash G Dinmohamed8,3,9,10.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33441537      PMCID： PMC7806661          DOI： 10.1038/s41408-020-00399-8

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  16 in total

1.  Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis.

Authors:  Yazan Migdady; Mohammed Salhab; Nam H Dang; Merry J Markham; Adam J Olszewski
Journal:  Leuk Lymphoma       Date:  2015-12-23

2.  Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.

Authors:  Eric M Ammann; Tait D Shanafelt; Kara B Wright; Bradley D McDowell; Brian K Link; Elizabeth A Chrischilles
Journal:  Leuk Lymphoma       Date:  2017-07-18

3.  Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands.

Authors:  Saskia A M van de Schans; Liza N van Steenbergen; Jan Willem W Coebergh; Maryska L G Janssen-Heijnen; Dick Johan van Spronsen
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

4.  First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.

Authors:  Ian W Flinn; Richard van der Jagt; Brad Kahl; Peter Wood; Tim Hawkins; David MacDonald; David Simpson; Kathryn Kolibaba; Samar Issa; Julie Chang; Judith Trotman; Doreen Hallman; Ling Chen; John M Burke
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

5.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Authors:  Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

6.  Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.

Authors:  Emmanuel Gyan; Anne Sonet; Pauline Brice; Bruno Anglaret; Kamel Laribi; Christophe Fruchart; Hervé Tilly; Carla Araujo; Pierre Soubeyran; Hugo Gonzalez; Nadine Morineau; Emmanuelle Nicolas-Virelizier; Hervé Ghesquières; Bruno Salles; Réda Bouabdallah; Hubert Orfeuvre; Jonathan Fahri; Olivier Couturier; Luc Xerri; Pierre Feugier
Journal:  Br J Haematol       Date:  2018-08-16       Impact factor: 6.998

7.  Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.

Authors:  Milena Sant; Pamela Minicozzi; Morgane Mounier; Lesley A Anderson; Hermann Brenner; Bernd Holleczek; Rafael Marcos-Gragera; Marc Maynadié; Alain Monnereau; Gemma Osca-Gelis; Otto Visser; Roberta De Angelis
Journal:  Lancet Oncol       Date:  2014-07-13       Impact factor: 41.316

8.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

9.  Conditional relative survival among long-term survivors of adolescent and young adult cancers.

Authors:  Chelsea Anderson; Andrew B Smitherman; Hazel B Nichols
Journal:  Cancer       Date:  2018-05-09       Impact factor: 6.860

10.  Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

Authors:  Brad S Kahl; Fangxin Hong; Michael E Williams; Randy D Gascoyne; Lynne I Wagner; John C Krauss; Thomas M Habermann; Lode J Swinnen; Stephen J Schuster; Christopher G Peterson; Mark D Sborov; S Eric Martin; Matthias Weiss; W Christopher Ehmann; Sandra J Horning
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.